Home › Funds › Sicart Associates LLC › IONS
Sicart Associates LLC position in IONS
IONIS PHARMACEUTICALS INC · Health Care
Sicart Associates LLC reported holding 159,294 shares of IONS (IONIS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$6.8M, representing 1.66% of its reported portfolio and ranking #20 among its reported holdings. Sicart Associates LLC has disclosed IONS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Sicart Associates LLC's IONS position evolved
Sicart Associates LLC first disclosed a stake in IONS in Q3 2023 at 203,132 shares (US$9.2M). The position peaked in Q4 2025 at 163,557 shares, worth US$12.9M. Across 13 filings, Sicart Associates LLC increased the stake 1 time(s), trimmed it 6 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 159,294 shares valued at US$6.8M — a reduction of -1,400 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 203.13K | $9.21M | New |
| Q4 2023 | 194.29K | $9.83M | Reduce |
| Q1 2024 | 193.99K | $8.41M | Hold |
| Q2 2024 | 191.52K | $9.13M | Reduce |
| Q3 2024 | 191.52K | $7.67M | Hold |
| Q4 2024 | 185.82K | $6.50M | Reduce |
| Q1 2025 | 185.65K | $5.60M | Hold |
| Q2 2025 | 185.30K | $7.32M | Hold |
| Q3 2025 | 164.32K | $10.75M | Reduce |
| Q4 2025 | 163.56K | $12.94M | Hold |
| Q1 2026 | 159.41K | $11.97M | Reduce |
| Q2 2026 | 160.69K | $12.74M | Add |
| Q3 2026 | 159.29K | $6.84M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IONS and 13F data
IONS (IONIS PHARMACEUTICALS INC) is a Health Care company. 34 other funds we track also report a position in IONS — the largest reported positions include Two Sigma Investments (US$495.7M), TWO SIGMA ADVISERS, LP (US$241.5M), Deep Track Capital, LP (US$174.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IONS
- Two Sigma Investments 6.25M sh · $495.75M · Q2 2026
- TWO SIGMA ADVISERS, LP 3.05M sh · $241.45M · Q4 2025
- Deep Track Capital, LP 2.20M sh · $174.44M · Q2 2026
- BAKER BROS. ADVISORS LP 2.05M sh · $162.36M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 94.68M sh · $147.77M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 60.00M sh · $93.10M · Q2 2026
- Tweedy, Browne Co LLC 1.79M sh · $80.08M · Q3 2026
- Bellevue Group AG 972.26K sh · $77.09M · Q2 2026
- GROUPAMA ASSET MANAGMENT 937.08K sh · $75.20M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 787.26K sh · $62.42M · Q2 2026
More on Sicart Associates LLC
FAQ
How long has Sicart Associates LLC held IONS?
Sicart Associates LLC has disclosed IONS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Sicart Associates LLC's current position in IONS?
As of Q3 2026, Sicart Associates LLC holds 159.29K shares of IONS (IONIS PHARMACEUTICALS INC), valued at $6.84M, representing 1.66% of its reported portfolio and ranking #20.
Has Sicart Associates LLC been buying or selling IONS?
In the latest 13F filing (Q3 2026), Sicart Associates LLC reduced its position in IONS. The position peaked in Q4 2025 at 163.56K shares.
Which other funds hold IONS?
Other major institutional holders of IONS include Two Sigma Investments, TWO SIGMA ADVISERS, LP, Deep Track Capital, LP, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.